Sarepta (NASDAQ: SRPT) exec has 1,399 shares withheld for taxes

Rhea-AI Filing Summary

Sarepta Therapeutics, Inc. executive Louise Rodino-Klapac, President of R&D and Tech Ops, reported routine tax-related share dispositions. On March 9, 2026, a total of 1,399 shares of common stock were withheld by the company at $16.95 per share to cover tax obligations on vesting restricted stock units granted in 2022 and 2023. After these withholdings, she directly holds 226,271 shares of Sarepta common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodino-Klapac Louise

(Last) (First) (Middle)

215 FIRST STREET

SUITE 415

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D and Tech Ops

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		F(1)		504	D	$16.95	227,166	D
Common Stock	03/09/2026		F(2)		895	D	$16.95	226,271	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023.

2. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Louise Rodino-Klapac	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Sarepta Therapeutics (SRPT) report for Louise Rodino-Klapac?

The filing shows tax-related share withholdings, not an open-market trade. On March 9, 2026, Sarepta withheld 1,399 shares of common stock from Louise Rodino-Klapac to satisfy tax obligations tied to vesting restricted stock units.

How many Sarepta (SRPT) shares were withheld for taxes in this Form 4?

A total of 1,399 shares of Sarepta common stock were withheld. The filing details two F-code transactions: 504 shares and 895 shares, each at $16.95 per share, to cover tax withholding obligations on RSU vesting.

What is Louise Rodino-Klapac’s Sarepta (SRPT) shareholding after the reported tax withholdings?

After the March 9, 2026 tax-withholding transactions, Louise Rodino-Klapac directly holds 226,271 shares of Sarepta common stock. This figure reflects her post-transaction ownership as shown in the Form 4 for the final F-code entry.

What triggered the share withholdings reported in Sarepta (SRPT) executive’s Form 4?

The withholdings were triggered by vesting restricted stock units. Footnotes explain that shares were withheld to satisfy tax obligations on RSUs granted on March 7, 2022 and March 6, 2023, a common administrative process.

Were the Sarepta (SRPT) insider transactions open-market sales or routine tax withholding?

The transactions were routine tax-withholding dispositions, not open-market sales. Code F in the Form 4 and the footnotes specify that shares were delivered to the company to cover tax liabilities associated with RSU vesting.